Last reviewed · How we verify
Hemophilia A — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Qfitlia | FITUSIRAN | Genzyme Corp | Antithrombin-directed RNA Interaction [EPC] | 2025-01-01 | ||
| PF-07202954 Single Dose | pf-07202954-single-dose | Pfizer | Unknown | Unknown | ||
| Xyntha | xyntha | Pfizer | Recombinant protein therapy | Coagulation factor VIII |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Hemophilia A
- Genzyme Corp · 1 drug in Hemophilia A
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hemophilia A:
- Hemophilia A treatment updates — RSS
- Hemophilia A treatment updates — Atom
- Hemophilia A treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hemophilia A — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hemophilia-a. Accessed 2026-06-10.
Related
- Hemophilia A full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing